

Detection Rates, Pre-Test Carrier Risks, and Post-Test Residual Risks (Sorted by Disorder)

The detection rates and risks set forth below were derived using publicly available information, including gnomAD (<https://gnomad.broadinstitute.org>) and ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>), and the rates were extrapolated using appropriate scientific methodologies. Published studies were used to derive individual carrier risks for CYP21A2, HBA1/HBA2 and SMN1. As additional clinical evidence is available, the data in these charts may be updated from time to time. These data are provided for general informational purposes only and are not intended as a substitute for professional medical judgment or medical advice.

For unknown or mixed ethnicity, consider using the ethnic background with the most conservative risk estimates.

N/A= Not Available

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|-------------|-------|---------------------------------|--------------------|-------------------------|--|--|
| 3M syndrome | CCDC8 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | CUL7 | African/African American | 99 | 1 in 305 | 1 in 30,000 | 1 in 120,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | OBSL1 | African/African American | 98 | 1 in 186 | 1 in 9,300 | 1 in 37,000 |
| | | Latino/Admixed American | 99 | 1 in 332 | 1 in 33,000 | 1 in 130,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 97 | 1 in 220 | 1 in 7,300 | 1 in 29,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 209 | 1 in 10,000 | 1 in 40,000 |
| | | South Asian | 97 | 1 in 299 | 1 in 9,900 | 1 in 40,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | 1 in 226 | 1 in 11,000 | 1 in 44,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|--------------|---------------------------------|--------------------|-------------------------|--|--|
| 3-Methylcrotonyl-CoA carboxylase deficiency | <i>MCCC1</i> | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | 1 in 390 | 1 in 39,000 | 1 in 160,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 444 | 1 in 44,000 | 1 in 180,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 472 | 1 in 47,000 | 1 in 190,000 |
| | <i>MCCC2</i> | African/African American | 99 | 1 in 377 | 1 in 38,000 | 1 in 150,000 |
| | | Latino/Admixed American | 99 | 1 in 123 | 1 in 12,000 | 1 in 48,000 |
| | | Ashkenazi Jewish | 99 | 1 in 192 | 1 in 19,000 | 1 in 76,000 |
| | | East Asian | 99 | 1 in 310 | 1 in 31,000 | 1 in 120,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 249 | 1 in 25,000 | 1 in 100,000 |
| | | South Asian | 99 | 1 in 464 | 1 in 46,000 | 1 in 180,000 |
| | | Other (population not assigned) | 99 | 1 in 168 | 1 in 17,000 | 1 in 68,000 |
| | | US general population | 99 | 1 in 217 | 1 in 22,000 | 1 in 88,000 |
| Abetalipoproteinemia | <i>MTTP</i> | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 187 | 1 in 19,000 | 1 in 76,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Achromatopsia | <i>CNGB3</i> | African/African American | 98 | 1 in 436 | 1 in 22,000 | 1 in 88,000 |
| | | Latino/Admixed American | 97 | 1 in 423 | 1 in 14,000 | 1 in 56,000 |
| | | Ashkenazi Jewish | 99 | 1 in 272 | 1 in 27,000 | 1 in 110,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | 1 in 172 | 1 in 5,700 | 1 in 23,000 |
| | | Non-Finnish European/Caucasian | 97 | 1 in 119 | 1 in 3,900 | 1 in 16,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | 1 in 149 | 1 in 7,400 | 1 in 30,000 |
| | | US general population | 97 | 1 in 163 | 1 in 5,400 | 1 in 22,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|-------------------------------|---------|---------------------------------|--------------------|-------------------------|--|--|
| Acrodermatitis enteropathica | SLC39A4 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | 1 in 278 | 1 in 9,200 | 1 in 37,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 386 | 1 in 19,000 | 1 in 76,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Acute infantile liver failure | LARS1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | 1 in 481 | 1 in 48,000 | 1 in 190,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 472 | 1 in 47,000 | 1 in 190,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | NBAS | African/African American | 98 | 1 in 198 | 1 in 9,900 | 1 in 40,000 |
| | | Latino/Admixed American | 98 | 1 in 228 | 1 in 11,000 | 1 in 44,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | 1 in 212 | 1 in 21,000 | 1 in 84,000 |
| | | Finnish | 98 | 1 in 244 | 1 in 12,000 | 1 in 48,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 105 | 1 in 10,000 | 1 in 40,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | 1 in 118 | 1 in 5,900 | 1 in 24,000 |
| | | US general population | 99 | 1 in 130 | 1 in 13,000 | 1 in 52,000 |
| | TRMU | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | 1 in 400 | 1 in 20,000 | 1 in 80,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--------------------------------|----------|---------------------------------|--------------------|-------------------------|--|--|
| Adenosine deaminase deficiency | ADA | African/African American | 99 | 1 in 321 | 1 in 32,000 | 1 in 130,000 |
| | | Latino/Admixed American | 99 | 1 in 301 | 1 in 30,000 | 1 in 120,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 437 | 1 in 44,000 | 1 in 180,000 |
| | | South Asian | 99 | 1 in 340 | 1 in 34,000 | 1 in 140,000 |
| | | Other (population not assigned) | 99 | 1 in 390 | 1 in 39,000 | 1 in 160,000 |
| | | US general population | 99 | 1 in 391 | 1 in 39,000 | 1 in 160,000 |
| Adrenoleukodystrophy, X-linked | ABCD1 | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 99 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 99 | N/A | N/A | N/A |
| Agammaglobulinemia, X-linked | BTK | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 99 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 99 | N/A | N/A | N/A |
| Aicardi-Goutières syndrome | RNASEH2A | African/African American | 97 | 1 in 285 | 1 in 9,500 | 1 in 38,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---------------------------------|-------------------------------|---------------------------------|--------------------------|-------------------------|--|--|
| | RNASEH2B | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | 1 in 434 | 1 in 43,000 | 1 in 170,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 195 | 1 in 19,000 | 1 in 76,000 |
| | | South Asian | 99 | 1 in 295 | 1 in 29,000 | 1 in 120,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 260 | 1 in 26,000 | 1 in 100,000 |
| | RNASEH2C | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | SAMHD1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | Allan-Herndon-Dudley syndrome | SLC16A2 | African/African American | 99 | N/A | N/A |
| Latino/Admixed American | | | 99 | N/A | N/A | N/A |
| Ashkenazi Jewish | | | 99 | N/A | N/A | N/A |
| East Asian | | | 99 | N/A | N/A | N/A |
| Finnish | | | 99 | N/A | N/A | N/A |
| Non-Finnish European/Caucasian | | | 99 | N/A | N/A | N/A |
| South Asian | | | 99 | N/A | N/A | N/A |
| Other (population not assigned) | | | 99 | N/A | N/A | N/A |
| US general population | | | 99 | N/A | N/A | N/A |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|-----------|---------------------------------|--------------------|-------------------------|--|--|
| Alpha-mannosidosis | MAN2B1 | African/African American | 99 | 1 in 287 | 1 in 29,000 | 1 in 120,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 206 | 1 in 21,000 | 1 in 84,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 426 | 1 in 43,000 | 1 in 170,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 494 | 1 in 49,000 | 1 in 200,000 |
| Alpha-thalassemia | HBA1/HBA2 | African | 90 | 1 in 3 | N/A | N/A |
| | | American | 90 | 1 in 21 | N/A | N/A |
| | | Eastern Mediterranean | 90 | 1 in 5 | N/A | N/A |
| | | European | 90 | 1 in 44 | N/A | N/A |
| | | Southeast Asian | 90 | 1 in 2 | N/A | N/A |
| | | Western Pacific | 90 | 1 in 10 | N/A | N/A |
| Alpha-thalassemia X-linked intellectual disability syndrome | ATRX | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 97 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 99 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 99 | N/A | N/A | N/A |
| Alport syndrome | COL4A3 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--------------------|---------|---------------------------------|--------------------|-------------------------|--|--|
| | COL4A4 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 178 | 1 in 18,000 | 1 in 72,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 360 | 1 in 36,000 | 1 in 140,000 |
| | | South Asian | 99 | 1 in 463 | 1 in 46,000 | 1 in 180,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 438 | 1 in 44,000 | 1 in 180,000 |
| | COL4A5 | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 97 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 99 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 99 | N/A | N/A | N/A |
| Alström syndrome | ALMS1 | African/African American | 98 | 1 in 209 | 1 in 10,000 | 1 in 40,000 |
| | | Latino/Admixed American | 98 | 1 in 307 | 1 in 15,000 | 1 in 60,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | 1 in 154 | 1 in 7,700 | 1 in 31,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 151 | 1 in 7,500 | 1 in 30,000 |
| | | South Asian | 98 | 1 in 284 | 1 in 14,000 | 1 in 56,000 |
| | | Other (population not assigned) | 98 | 1 in 334 | 1 in 17,000 | 1 in 68,000 |
| | | US general population | 98 | 1 in 178 | 1 in 8,800 | 1 in 35,000 |
| Andermann syndrome | SLC12A6 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|---------|---------------------------------|--------------------|-------------------------|--|--|
| Arginase deficiency | ARG1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | 1 in 486 | 1 in 49,000 | 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Argininosuccinic aciduria | ASL | African/African American | 99 | 1 in 452 | 1 in 45,000 | 1 in 180,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 94 | 1 in 9,300 | 1 in 37,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 142 | 1 in 14,000 | 1 in 56,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 116 | 1 in 12,000 | 1 in 48,000 |
| | | US general population | 99 | 1 in 193 | 1 in 19,000 | 1 in 76,000 |
| Aromatic l-amino acid decarboxylase deficiency | DDC | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | 1 in 134 | 1 in 13,000 | 1 in 52,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Arterial tortuosity syndrome | SLC2A10 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|---------|---------------------------------|--------------------|-------------------------|--|--|
| Arthrogryposis, mental retardation, and seizures (AMRS) | SLC35A3 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 373 | 1 in 37,000 | 1 in 150,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Asparagine synthetase deficiency | ASNS | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Aspartylglucosaminuria | AGA | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | 1 in 61 | 1 in 6,000 | 1 in 24,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 99 | 1 in 264 | 1 in 26,000 | 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Ataxia with vitamin E deficiency | TTPA | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|-------|---------------------------------|--------------------|-------------------------|--|--|
| Ataxia-telangiectasia | ATM | African/African American | 98 | 1 in 234 | 1 in 12,000 | 1 in 48,000 |
| | | Latino/Admixed American | 99 | 1 in 259 | 1 in 26,000 | 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | 1 in 275 | 1 in 14,000 | 1 in 56,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 155 | 1 in 7,700 | 1 in 31,000 |
| | | South Asian | 99 | 1 in 348 | 1 in 35,000 | 1 in 140,000 |
| | | Other (population not assigned) | 98 | 1 in 207 | 1 in 10,000 | 1 in 40,000 |
| | | US general population | 98 | 1 in 181 | 1 in 9,000 | 1 in 36,000 |
| ATP7A-related copper transport disorders, includes Menkes syndrome | ATP7A | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 98 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 98 | N/A | N/A | N/A |
| Atransferrinemia | TF | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Autoimmune polyglandular syndrome type 1 | AIRE | African/African American | 99 | 1 in 426 | 1 in 43,000 | 1 in 170,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | 1 in 302 | 1 in 30,000 | 1 in 120,000 |
| | | Finnish | 99 | 1 in 93 | 1 in 9,200 | 1 in 37,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 207 | 1 in 10,000 | 1 in 40,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | 1 in 181 | 1 in 9,000 | 1 in 36,000 |
| | | US general population | 98 | 1 in 259 | 1 in 13,000 | 1 in 52,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|---------|---------------------------------|--------------------|-------------------------|--|--|
| Autosomal recessive congenital ichthyosis (ARCI) | ABCA12 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 423 | 1 in 21,000 | 1 in 84,000 |
| | | South Asian | 97 | 1 in 203 | 1 in 6,700 | 1 in 27,000 |
| | | Other (population not assigned) | 99 | 1 in 325 | 1 in 32,000 | 1 in 130,000 |
| | | US general population | 98 | 1 in 458 | 1 in 23,000 | 1 in 92,000 |
| | ALOX12B | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | ALOXE3 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 176 | 1 in 18,000 | 1 in 72,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 257 | 1 in 26,000 | 1 in 100,000 |
| | | US general population | 99 | 1 in 244 | 1 in 24,000 | 1 in 96,000 |
| | CERS3 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|----------|---------|---------------------------------|--------------------|-------------------------|--|--|
| | CYP4F22 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | LIPN | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | NIPAL4 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 391 | 1 in 39,000 | 1 in 160,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | PNPLA1 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | 1 in 492 | 1 in 49,000 | 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|---------|---------------------------------|--------------------|-------------------------|--|--|
| | SDR9C7 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 416 | 1 in 42,000 | 1 in 170,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | SLC27A4 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | TGM1 | African/African American | 99 | 1 in 275 | 1 in 27,000 | 1 in 110,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 463 | 1 in 46,000 | 1 in 180,000 |
| | | East Asian | 99 | 1 in 295 | 1 in 29,000 | 1 in 120,000 |
| | | Finnish | 99 | 1 in 195 | 1 in 19,000 | 1 in 76,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 221 | 1 in 22,000 | 1 in 88,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 265 | 1 in 26,000 | 1 in 100,000 |
| | | US general population | 99 | 1 in 265 | 1 in 26,000 | 1 in 100,000 |
| Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) | SACS | African/African American | 98 | 1 in 233 | 1 in 12,000 | 1 in 48,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 307 | 1 in 15,000 | 1 in 60,000 |
| | | South Asian | 98 | 1 in 474 | 1 in 24,000 | 1 in 96,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | 1 in 335 | 1 in 17,000 | 1 in 68,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--------------------------------------|-------|---------------------------------|--------------------|-------------------------|--|--|
| Axonal neuropathy with neuromyotonia | HINT1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Bardet-Biedl syndrome | ARL6 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | BBS1 | African/African American | 99 | 1 in 266 | 1 in 27,000 | 1 in 110,000 |
| | | Latino/Admixed American | 99 | 1 in 419 | 1 in 42,000 | 1 in 170,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 290 | 1 in 29,000 | 1 in 120,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 149 | 1 in 15,000 | 1 in 60,000 |
| | | South Asian | 99 | 1 in 187 | 1 in 19,000 | 1 in 76,000 |
| | | Other (population not assigned) | 99 | 1 in 274 | 1 in 27,000 | 1 in 110,000 |
| | | US general population | 99 | 1 in 191 | 1 in 19,000 | 1 in 76,000 |
| | BBS2 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | 1 in 126 | 1 in 13,000 | 1 in 52,000 |
| | | East Asian | 99 | 1 in 192 | 1 in 19,000 | 1 in 76,000 |
| | | Finnish | 99 | 1 in 499 | 1 in 50,000 | 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 423 | 1 in 42,000 | 1 in 170,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | 1 in 479 | 1 in 48,000 | 1 in 190,000 |
| | | US general population | 99 | 1 in 499 | 1 in 50,000 | 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|----------|------|---------------------------------|--------------------|-------------------------|--|--|
| | BBS4 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | BBS5 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | BBS7 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | BBS9 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|----------|---------|---------------------------------|--------------------|-------------------------|--|--|
| | BBS10 | African/African American | 97 | 1 in 410 | 1 in 14,000 | 1 in 56,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | 1 in 305 | 1 in 10,000 | 1 in 40,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 97 | 1 in 248 | 1 in 8,200 | 1 in 33,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | 1 in 438 | 1 in 22,000 | 1 in 88,000 |
| | | US general population | 97 | 1 in 329 | 1 in 11,000 | 1 in 44,000 |
| | BBS12 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | MKKS | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | SDCCAG8 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|----------------------------------|--------|---------------------------------|--------------------|-------------------------|--|--|
| | TTC8 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Bare lymphocyte syndrome type II | CIITA | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | RFX5 | African/African American | 99 | 1 in 475 | 1 in 47,000 | 1 in 190,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | 1 in 406 | 1 in 41,000 | 1 in 160,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | RFXANK | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|------------------|---------|---------------------------------|--------------------|-------------------------|--|--|
| | RFXAP | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Barth syndrome | TFAZZIN | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 99 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 99 | N/A | N/A | N/A |
| Bartter syndrome | BSND | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | KCNJ1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | 1 in 426 | 1 in 43,000 | 1 in 170,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | 1 in 205 | 1 in 20,000 | 1 in 80,000 |
| | | Other (population not assigned) | 99 | 1 in 178 | 1 in 18,000 | 1 in 72,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|---------|---------------------------------|--------------------|-------------------------|--|--|
| | SLC12A1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | 1 in 465 | 1 in 46,000 | 1 in 180,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Basal ganglia disease, biotin-thiamine-responsive | SLC19A3 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Beta-hemoglobinopathies, includes sickle cell disease and beta-thalassemias | HBB | African/African American | 99 | 1 in 9 | 1 in 800 | 1 in 3,200 |
| | | Latino/Admixed American | 99 | 1 in 162 | 1 in 16,000 | 1 in 64,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 98 | 1 in 107 | 1 in 5,300 | 1 in 21,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 256 | 1 in 26,000 | 1 in 100,000 |
| | | South Asian | 99 | 1 in 28 | 1 in 2,700 | 1 in 11,000 |
| | | Other (population not assigned) | 99 | 1 in 116 | 1 in 12,000 | 1 in 48,000 |
| | | US general population | 99 | 1 in 52 | 1 in 5,100 | 1 in 20,000 |
| Beta-ketothiolase deficiency | ACAT1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | 1 in 158 | 1 in 16,000 | 1 in 64,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | 1 in 383 | 1 in 19,000 | 1 in 76,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 431 | 1 in 43,000 | 1 in 170,000 |
| | | US general population | 99 | 1 in 389 | 1 in 39,000 | 1 in 160,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|------------------------|-----------------------------------|---------------------------------|--------------------|-------------------------|--|--|
| Beta-mannosidosis | MANBA | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Biotinidase deficiency | <i>BTD (profound and partial)</i> | African/African American | 99 | 1 in 53 | 1 in 5,200 | 1 in 21,000 |
| | | Latino/Admixed American | 99 | 1 in 25 | 1 in 2,400 | 1 in 9,600 |
| | | Ashkenazi Jewish | 99 | 1 in 16 | 1 in 1,500 | 1 in 6,000 |
| | | East Asian | 99 | 1 in 389 | 1 in 39,000 | 1 in 160,000 |
| | | Finnish | 99 | 1 in 10 | 1 in 900 | 1 in 3,600 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 12 | 1 in 1,100 | 1 in 4,400 |
| | | South Asian | 99 | 1 in 13 | 1 in 1,200 | 1 in 4,800 |
| | | Other (population not assigned) | 99 | 1 in 16 | 1 in 1,500 | 1 in 6,000 |
| | | US general population | 99 | 1 in 16 | 1 in 1,500 | 1 in 6,000 |
| | <i>BTD (profound)</i> | African/African American | 99 | 1 in 159 | 1 in 16,000 | 1 in 64,000 |
| | | Latino/Admixed American | 99 | 1 in 259 | 1 in 26,000 | 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | 1 in 422 | 1 in 42,000 | 1 in 170,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 168 | 1 in 17,000 | 1 in 68,000 |
| | | South Asian | 99 | 1 in 191 | 1 in 9,500 | 1 in 38,000 |
| | | Other (population not assigned) | 99 | 1 in 265 | 1 in 26,000 | 1 in 100,000 |
| | | US general population | 99 | 1 in 185 | 1 in 18,000 | 1 in 72,000 |
| Bloom syndrome | BLM | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 97 | 1 in 123 | 1 in 4,100 | 1 in 16,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 327 | 1 in 33,000 | 1 in 130,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 98 | 1 in 384 | 1 in 19,000 | 1 in 76,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|--------|---------------------------------|--------------------|-------------------------|--|--|
| Brittle cornea syndrome | PRDM5 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | ZNF469 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 99 | 1 in 106 | 1 in 11,000 | 1 in 44,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Canavan disease | ASPA | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 48 | 1 in 4,700 | 1 in 19,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 254 | 1 in 25,000 | 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 314 | 1 in 31,000 | 1 in 120,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Carbamoyl phosphate synthetase I deficiency | CPS1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|----------|---------------------------------|--------------------|-------------------------|--|--|
| Carnitine palmitoyltransferase I deficiency | CPT1A | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 274 | 1 in 27,000 | 1 in 110,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 349 | 1 in 35,000 | 1 in 140,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Carnitine palmitoyltransferase II deficiency | CPT2 | African/African American | 99 | 1 in 231 | 1 in 23,000 | 1 in 92,000 |
| | | Latino/Admixed American | 99 | 1 in 299 | 1 in 30,000 | 1 in 120,000 |
| | | Ashkenazi Jewish | 99 | 1 in 40 | 1 in 3,900 | 1 in 16,000 |
| | | East Asian | 99 | 1 in 301 | 1 in 30,000 | 1 in 120,000 |
| | | Finnish | 99 | 1 in 242 | 1 in 24,000 | 1 in 96,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 178 | 1 in 18,000 | 1 in 72,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 169 | 1 in 17,000 | 1 in 68,000 |
| | | US general population | 99 | 1 in 204 | 1 in 20,000 | 1 in 80,000 |
| Carnitine-acylcarnitine translocase deficiency | SLC25A20 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | 1 in 497 | 1 in 50,000 | 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Carpenter syndrome | RAB23 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|-------|---------------------------------|--------------------|-------------------------|--|--|
| Cartilage-hair hypoplasia | RMRP | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | 1 in 184 | 1 in 9,200 | 1 in 37,000 |
| | | Ashkenazi Jewish | 99 | 1 in 70 | 1 in 6,900 | 1 in 28,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 55 | 1 in 5,400 | 1 in 22,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 292 | 1 in 29,000 | 1 in 120,000 |
| | | South Asian | 99 | 1 in 385 | 1 in 38,000 | 1 in 150,000 |
| | | Other (population not assigned) | 98 | 1 in 92 | 1 in 4,600 | 1 in 18,000 |
| | | US general population | 99 | 1 in 278 | 1 in 28,000 | 1 in 110,000 |
| Cerebellar hypoplasia, VLDLR-associated | VLDLR | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Cerebral creatine deficiency syndromes | GAMT | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | GATM | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--------------------------------|---------|---------------------------------|--------------------|-------------------------|--|--|
| | SLC6A8 | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 97 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 97 | N/A | N/A | N/A |
| Cerebrotendinous xanthomatosis | CYP27A1 | African/African American | 99 | 1 in 309 | 1 in 31,000 | 1 in 120,000 |
| | | Latino/Admixed American | 99 | 1 in 316 | 1 in 32,000 | 1 in 130,000 |
| | | Ashkenazi Jewish | 99 | 1 in 300 | 1 in 30,000 | 1 in 120,000 |
| | | East Asian | 99 | 1 in 122 | 1 in 12,000 | 1 in 48,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 299 | 1 in 30,000 | 1 in 120,000 |
| | | South Asian | 99 | 1 in 312 | 1 in 31,000 | 1 in 120,000 |
| | | Other (population not assigned) | 99 | 1 in 293 | 1 in 29,000 | 1 in 120,000 |
| | | US general population | 99 | 1 in 288 | 1 in 29,000 | 1 in 120,000 |
| Chediak-Higashi syndrome | LYST | African/African American | 99 | 1 in 397 | 1 in 40,000 | 1 in 160,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Choreacanthocytosis | VPS13A | African/African American | 98 | 1 in 367 | 1 in 18,000 | 1 in 72,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | 1 in 400 | 1 in 20,000 | 1 in 80,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 352 | 1 in 18,000 | 1 in 72,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | 1 in 420 | 1 in 21,000 | 1 in 84,000 |
| | | US general population | 98 | 1 in 387 | 1 in 19,000 | 1 in 76,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|-------------------------------|------|---------------------------------|--------------------|-------------------------|--|--|
| Chronic granulomatous disease | CYBA | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | CYBB | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 97 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 97 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 99 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 99 | N/A | N/A | N/A |
| | NCF2 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | NCF4 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 491 | 1 in 49,000 | 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---------------|----------|---------------------------------|--------------------|-------------------------|--|--|
| Ciliopathies | CEP290 | African/African American | 99 | 1 in 132 | 1 in 13,000 | 1 in 52,000 |
| | | Latino/Admixed American | 98 | 1 in 194 | 1 in 9,700 | 1 in 39,000 |
| | | Ashkenazi Jewish | 99 | 1 in 440 | 1 in 44,000 | 1 in 180,000 |
| | | East Asian | 99 | 1 in 80 | 1 in 7,900 | 1 in 32,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 109 | 1 in 5,400 | 1 in 22,000 |
| | | South Asian | 98 | 1 in 214 | 1 in 11,000 | 1 in 44,000 |
| | | Other (population not assigned) | 98 | 1 in 169 | 1 in 8,400 | 1 in 34,000 |
| | | US general population | 98 | 1 in 122 | 1 in 6,100 | 1 in 24,000 |
| | MKS1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | 1 in 285 | 1 in 14,000 | 1 in 56,000 |
| | | Finnish | 97 | 1 in 72 | 1 in 2,400 | 1 in 9,600 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 266 | 1 in 13,000 | 1 in 52,000 |
| | | South Asian | 98 | 1 in 459 | 1 in 23,000 | 1 in 92,000 |
| | | Other (population not assigned) | 97 | 1 in 232 | 1 in 7,700 | 1 in 31,000 |
| | | US general population | 98 | 1 in 342 | 1 in 17,000 | 1 in 68,000 |
| Citrullinemia | ASS1 | African/African American | 99 | 1 in 325 | 1 in 32,000 | 1 in 130,000 |
| | | Latino/Admixed American | 99 | 1 in 292 | 1 in 29,000 | 1 in 120,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 338 | 1 in 34,000 | 1 in 140,000 |
| | | South Asian | 99 | 1 in 218 | 1 in 22,000 | 1 in 88,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 334 | 1 in 33,000 | 1 in 130,000 |
| | SLC25A13 | African/African American | 98 | 1 in 406 | 1 in 20,000 | 1 in 80,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | 1 in 266 | 1 in 27,000 | 1 in 110,000 |
| | | East Asian | 98 | 1 in 58 | 1 in 2,900 | 1 in 12,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | 1 in 486 | 1 in 49,000 | 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 494 | 1 in 49,000 | 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|---------|---------------------------------|--------------------|-------------------------|--|--|
| Coats plus syndrome and dyskeratosis congenita, CTC1-related | CTC1 | African/African American | 99 | 1 in 453 | 1 in 45,000 | 1 in 180,000 |
| | | Latino/Admixed American | 98 | 1 in 298 | 1 in 15,000 | 1 in 60,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | 1 in 237 | 1 in 24,000 | 1 in 96,000 |
| | | Finnish | 97 | 1 in 115 | 1 in 3,800 | 1 in 15,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 263 | 1 in 13,000 | 1 in 52,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 97 | 1 in 171 | 1 in 5,700 | 1 in 23,000 |
| | | US general population | 98 | 1 in 281 | 1 in 14,000 | 1 in 56,000 |
| Cockayne syndrome | ERCC6 | African/African American | 98 | 1 in 314 | 1 in 16,000 | 1 in 64,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | 1 in 420 | 1 in 42,000 | 1 in 170,000 |
| | | Finnish | 99 | 1 in 265 | 1 in 26,000 | 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 331 | 1 in 33,000 | 1 in 130,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 378 | 1 in 38,000 | 1 in 150,000 |
| | ERCC8 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 240 | 1 in 24,000 | 1 in 96,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Coffin-Lowry syndrome | RPS6KA3 | African/African American | 99 | N/A | N/A | N/A |
| | | Latino/Admixed American | 99 | N/A | N/A | N/A |
| | | Ashkenazi Jewish | 99 | N/A | N/A | N/A |
| | | East Asian | 99 | N/A | N/A | N/A |
| | | Finnish | 99 | N/A | N/A | N/A |
| | | Non-Finnish European/Caucasian | 97 | N/A | N/A | N/A |
| | | South Asian | 99 | N/A | N/A | N/A |
| | | Other (population not assigned) | 99 | N/A | N/A | N/A |
| | | US general population | 97 | N/A | N/A | N/A |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|--------|---------------------------------|--------------------|-------------------------|--|--|
| Cohen syndrome | VPS13B | African/African American | 99 | 1 in 217 | 1 in 22,000 | 1 in 88,000 |
| | | Latino/Admixed American | 99 | 1 in 457 | 1 in 46,000 | 1 in 180,000 |
| | | Ashkenazi Jewish | 97 | 1 in 280 | 1 in 9,300 | 1 in 37,000 |
| | | East Asian | 99 | 1 in 271 | 1 in 27,000 | 1 in 110,000 |
| | | Finnish | 97 | 1 in 123 | 1 in 4,100 | 1 in 16,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 225 | 1 in 11,000 | 1 in 44,000 |
| | | South Asian | 98 | 1 in 323 | 1 in 16,000 | 1 in 64,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | 1 in 254 | 1 in 13,000 | 1 in 52,000 |
| Cold-induced sweating syndrome, includes Crisponi syndrome | CLCF1 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | CRLF1 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Combined malonic and methylmalonic aciduria | ACSF3 | African/African American | 99 | 1 in 204 | 1 in 20,000 | 1 in 80,000 |
| | | Latino/Admixed American | 99 | 1 in 175 | 1 in 17,000 | 1 in 68,000 |
| | | Ashkenazi Jewish | 99 | 1 in 341 | 1 in 34,000 | 1 in 140,000 |
| | | East Asian | 99 | 1 in 302 | 1 in 30,000 | 1 in 120,000 |
| | | Finnish | 99 | 1 in 331 | 1 in 33,000 | 1 in 130,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 71 | 1 in 7,000 | 1 in 28,000 |
| | | South Asian | 99 | 1 in 297 | 1 in 30,000 | 1 in 120,000 |
| | | Other (population not assigned) | 99 | 1 in 121 | 1 in 12,000 | 1 in 48,000 |
| | | US general population | 99 | 1 in 94 | 1 in 9,300 | 1 in 37,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|-------|---------------------------------|--------------------|-------------------------|--|--|
| Combined oxidative phosphorylation deficiency | GFM1 | African/African American | 98 | 1 in 459 | 1 in 23,000 | 1 in 92,000 |
| | | Latino/Admixed American | 99 | 1 in 485 | 1 in 48,000 | 1 in 190,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 432 | 1 in 22,000 | 1 in 88,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | 1 in 456 | 1 in 46,000 | 1 in 180,000 |
| | TSFM | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 35 | 1 in 3,400 | 1 in 14,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 483 | 1 in 48,000 | 1 in 190,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 307 | 1 in 31,000 | 1 in 120,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Combined pituitary hormone deficiency | LHX3 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | PROP1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--------------------------------|---------|---------------------------------|--------------------|-------------------------|--|--|
| Congenital adrenal hyperplasia | CYP11A1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | CYP11B1 | African/African American | 99 | 1 in 408 | 1 in 41,000 | 1 in 160,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | 1 in 332 | 1 in 33,000 | 1 in 130,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | CYP17A1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 98 | 1 in 334 | 1 in 17,000 | 1 in 68,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | CYP21A2 | African American | 82 | 1 in 79 | 1 in 430 | 1 in 1700 |
| | | Ashkenazi Jewish | 90 | 1 in 40 | 1 in 390 | 1 in 1600 |
| | | Asian | 92 | 1 in 62 | 1 in 760 | 1 in 3000 |
| | | Indian | 87 | 1 in 40 | 1 in 300 | 1 in 1200 |
| | | European | 88 | 1 in 70 | 1 in 580 | 1 in 2300 |
| | | Hispanic American | 89 | 1 in 73 | 1 in 660 | 1 in 2600 |
| Other | | 90 | 1 in 70 | 1 in 690 | 1 in 2800 | |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result | |
|---------------------------------|---|---------------------------------|--------------------------|-------------------------|--|--|-----|
| | HSD3B2 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 | |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 | |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | POR | African/African American | 98 | 1 in 450 | 1 in 22,000 | 1 in 88,000 | |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 | |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Finnish | 98 | 1 in 273 | 1 in 14,000 | 1 in 56,000 | |
| | | Non-Finnish European/Caucasian | 99 | 1 in 312 | 1 in 31,000 | 1 in 120,000 | |
| | | South Asian | 98 | 1 in 456 | 1 in 23,000 | 1 in 92,000 | |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | US general population | 99 | 1 in 370 | 1 in 37,000 | 1 in 150,000 | |
| | STAR | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | East Asian | 99 | 1 in 406 | 1 in 41,000 | 1 in 160,000 | |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 | |
| | Congenital adrenal hypoplasia, X-linked | NROB1 | African/African American | 99 | N/A | N/A | N/A |
| | | | Latino/Admixed American | 97 | N/A | N/A | N/A |
| Ashkenazi Jewish | | | 99 | N/A | N/A | N/A | |
| East Asian | | | 99 | N/A | N/A | N/A | |
| Finnish | | | 99 | N/A | N/A | N/A | |
| Non-Finnish European/Caucasian | | | 99 | N/A | N/A | N/A | |
| South Asian | | | 99 | N/A | N/A | N/A | |
| Other (population not assigned) | | | 99 | N/A | N/A | N/A | |
| US general population | | | 97 | N/A | N/A | N/A | |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|-------|---------------------------------|--------------------|-------------------------|--|--|
| Congenital amegakaryocytic thrombocytopenia | MPL | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | 1 in 59 | 1 in 5,800 | 1 in 23,000 |
| | | East Asian | 99 | 1 in 294 | 1 in 29,000 | 1 in 120,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 278 | 1 in 28,000 | 1 in 110,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | 1 in 301 | 1 in 30,000 | 1 in 120,000 |
| | | US general population | 99 | 1 in 340 | 1 in 34,000 | 1 in 140,000 |
| Congenital arthrogyrosis with anterior horn cell disease | GLE1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | 1 in 42 | 1 in 4,100 | 1 in 16,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | 1 in 442 | 1 in 44,000 | 1 in 180,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Congenital disorder of deglycosylation | NGLY1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | 1 in 444 | 1 in 22,000 | 1 in 88,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Congenital disorders of glycosylation | ALG1 | African/African American | 99 | 1 in 277 | 1 in 28,000 | 1 in 110,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 407 | 1 in 41,000 | 1 in 160,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 461 | 1 in 46,000 | 1 in 180,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---------------------------------|--------------------------------------|---------------------------------|--------------------------|-------------------------|--|--|
| | ALG6 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 330 | 1 in 33,000 | 1 in 130,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | 1 in 450 | 1 in 45,000 | 1 in 180,000 |
| | MPI | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | 1 in 323 | 1 in 32,000 | 1 in 130,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | PMM2 | African/African American | 99 | 1 in 225 | 1 in 22,000 | 1 in 88,000 |
| | | Latino/Admixed American | 99 | 1 in 116 | 1 in 12,000 | 1 in 48,000 |
| | | Ashkenazi Jewish | 99 | 1 in 65 | 1 in 6,400 | 1 in 26,000 |
| | | East Asian | 99 | 1 in 157 | 1 in 16,000 | 1 in 64,000 |
| | | Finnish | 99 | 1 in 58 | 1 in 5,700 | 1 in 23,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 63 | 1 in 6,200 | 1 in 25,000 |
| | | South Asian | 99 | 1 in 259 | 1 in 26,000 | 1 in 100,000 |
| | | Other (population not assigned) | 99 | 1 in 81 | 1 in 8,000 | 1 in 32,000 |
| | | US general population | 99 | 1 in 80 | 1 in 7,900 | 1 in 32,000 |
| | Congenital generalized lipodystrophy | AGPAT2 | African/African American | 99 | 1 in 217 | 1 in 22,000 |
| Latino/Admixed American | | | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Ashkenazi Jewish | | | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| East Asian | | | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| Finnish | | | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Non-Finnish European/Caucasian | | | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| South Asian | | | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Other (population not assigned) | | | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| US general population | | | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|--|---------|---------------------------------|--------------------|-------------------------|--|--|
| | CAVIN1 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| Congenital hydrocephalus 1 | CCDC88C | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Congenital insensitivity to pain with anhidrosis | NTRK1 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | 1 in 343 | 1 in 34,000 | 1 in 140,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Congenital myasthenic syndrome | CHAT | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|----------|-------|---------------------------------|--------------------|-------------------------|--|--|
| | CHRNE | African/African American | 98 | 1 in 465 | 1 in 23,000 | 1 in 92,000 |
| | | Latino/Admixed American | 97 | 1 in 420 | 1 in 14,000 | 1 in 56,000 |
| | | Ashkenazi Jewish | 97 | 1 in 153 | 1 in 5,100 | 1 in 20,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 97 | 1 in 348 | 1 in 12,000 | 1 in 48,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | COLQ | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 385 | 1 in 38,000 | 1 in 150,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | DOK7 | African/African American | 97 | 1 in 344 | 1 in 11,000 | 1 in 44,000 |
| | | Latino/Admixed American | 97 | 1 in 424 | 1 in 14,000 | 1 in 56,000 |
| | | Ashkenazi Jewish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 97 | 1 in 281 | 1 in 9,300 | 1 in 37,000 |
| | | South Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 97 | 1 in 324 | 1 in 11,000 | 1 in 44,000 |
| | GFPT1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|---|----------|---------------------------------|--------------------|-------------------------|--|--|
| | RAPSN | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | 1 in 340 | 1 in 34,000 | 1 in 140,000 |
| | | Ashkenazi Jewish | 99 | 1 in 247 | 1 in 25,000 | 1 in 100,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | 1 in 169 | 1 in 17,000 | 1 in 68,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | 1 in 451 | 1 in 45,000 | 1 in 180,000 |
| | | US general population | 99 | 1 in 227 | 1 in 23,000 | 1 in 92,000 |
| Corneal dystrophy and perceptive deafness | SLC4A11 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| Costeff syndrome | OPA3 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| Cutis laxa | ATP6V0A2 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | 1 in 441 | 1 in 15,000 | 1 in 60,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|----------|----------|---------------------------------|--------------------|-------------------------|--|--|
| | ATP6V1E1 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | EFEMP2 | African/African American | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | LTBP4 | African/African American | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Finnish | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | PYCR1 | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | East Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Finnish | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Non-Finnish European/Caucasian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | South Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Other (population not assigned) | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | US general population | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |

| Disorder | Gene | Ethnicity | Detection Rate (%) | Individual Carrier Risk | Individual Residual Risk After Negative Result | Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result |
|-----------------|------|---------------------------------|--------------------|-------------------------|--|--|
| Cystic fibrosis | CFTR | African/African American | 98 | 1 in 50 | 1 in 2,500 | 1 in 10,000 |
| | | Latino/Admixed American | 98 | 1 in 40 | 1 in 2,000 | 1 in 8,000 |
| | | Ashkenazi Jewish | 99 | 1 in 17 | 1 in 1,600 | 1 in 6,400 |
| | | East Asian | 98 | 1 in 163 | 1 in 8,100 | 1 in 32,000 |
| | | Finnish | 98 | 1 in 73 | 1 in 3,600 | 1 in 14,000 |
| | | Non-Finnish European/Caucasian | 98 | 1 in 21 | 1 in 1,000 | 1 in 4,000 |
| | | South Asian | 99 | 1 in 60 | 1 in 5,900 | 1 in 24,000 |
| | | Other (population not assigned) | 98 | 1 in 33 | 1 in 1,600 | 1 in 6,400 |
| | | US general population | 98 | 1 in 27 | 1 in 1,300 | 1 in 5,200 |
| Cystinosis | CTNS | African/African American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Latino/Admixed American | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Ashkenazi Jewish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | East Asian | 99 | < 1 in 500 | < 1 in 50,000 | < 1 in 200,000 |
| | | Finnish | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | Non-Finnish European/Caucasian | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | South Asian | 97 | < 1 in 500 | < 1 in 17,000 | < 1 in 68,000 |
| | | Other (population not assigned) | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |
| | | US general population | 98 | < 1 in 500 | < 1 in 25,000 | < 1 in 100,000 |